Corticoid Therapy in Acute Myocarditis
A legfontosabb adatok
- Ki végzi
- Assistance Publique - Hôpitaux de Paris
- Hol
- Franciaország25 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 3. fázis
- Résztvevők
- 420 fő, tervezett
- Kezdés
- 2025. febr. 1.
- Várható befejezés
- 2028. aug. 16.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Intravenous administration of Methylprednisolone
- Oral Prednisone
- Perfusion of placebo
- Oral Prednisone placebo
- A regiszteradat frissítve
- 2024. július 29.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with active acute myocarditis (inflammation of the heart muscle) and a weakened left heart chamber. It tests steroid medicines (Methylprednisolone, then Prednisone) against placebo, added to usual heart failure treatment.
- Életkor
- 18 years and older
- Nem
- All sexes
- A betegség stádiuma
- Active myocarditis with symptoms or ECG changes, a troponin rise (1,5 times the normal range), and diagnosis by cardiac MRI (Lake-Louise criteria) or heart biopsy (Dallas's criteria). Left heart pumping is reduced: LVEF < 50% and/or GLS < -16% on heart ultrasound.
- Korábbi kezelés
- A normal coronary angiography or CT scan (no narrowing > 50%) during the previous year is required. People who needed steroids for another autoimmune or inflammatory disease within 6 months before enrolment cannot join.
- Biomarker vagy leletérték
- Troponin rise of 1,5 times the normal range.
A részvétel fő kizáró okai
- Active coronary disease or other causes of chronic heart failure
- Myocarditis of another type needing steroids (giant cell, eosinophilic, cardiac sarcoidosis, immune checkpoint inhibitor)
- Pregnancy, breastfeeding, or no effective birth control in women who can become pregnant
- Infections or active viruses such as hepatitis, herpes, chickenpox or shingles, or other reasons steroids cannot be used
- Not speaking or understanding French
A regiszter feltételei, szó szerint
Mind a 19 feltétel megnézéseKevesebb
Ki vehet részt
- Age ≥ 18 years
- Written signed informed consent
- Affiliation to the French health care system or to another social protection scheme with the exception of State Medical Aid
- Active myocarditis defined by (all items are required):; Acute chest pain and/or unexplained heart failure and/or syncope and/or sustained ventricular arrhythmias and/or aborted sudden death and/or cardiogenic shock and/or ECG modification (atrioventricular block or bundle branch block or sinus arrest or ST or T waves change or ventricular arrhythmia or atrial fibrillation or abnormal Q waves); And troponin rise (1,5 times the normal range); And diagnosis of active myocarditis on Cardiac Magnetic Resonance (according to Lake-Louise criteria) or by histological evidence on endomyocardial biopsy (Dallas's criteria)
- Left-ventricular dysfunction defined as LVEF < 50% and/or GLS < -16% assessed with 2D-TTE
- Normal coronary angiography or CT Scan (without stenosis > 50%) during the previous year
Ki nem vehet részt
- Other auto-immune or inflammatory disease requiring corticosteroids treatment within 6 months before enrolment
- Concomitant participation in another clinical trial on medical product for human use, to a clinical investigation on a medical device, to interventional study involving human participants or in the exclusion period at the end of a previous clinical trial on medical product for human use, a clinical investigation on a medical device, or study involving human participants. Participation in non-interventional research is permitted
- Contra-indication linked to steroids (Methylprednisolone and Prednisone) according to summary of product characteristics:; Any infectious condition excluding the specified therapeutic indications of Methylprednisolone and Prednisone; Certain evolving viruses (notably hepatitis, herpes, chickenpox, shingles); Psychotic states not yet controlled by treatment; Recent live vaccines or live attenuated vaccines in patients receiving dosages greater than 20 mg/day of prednisone equivalent for more than two weeks and during the 3 months following the cessation of corticosteroid therapy (risk of generalized vaccine disease possibly fatal); Hypersensitivity to the active substances or to any of the excipients
- Contra-indication linked to auxiliary drugs according to respective summary of product characteristics:; Beta-blockade; Angiotensin-converting-enzyme inhibitor (ACE-I); Angiotensin receptor blockers (ARB); Mineralocorticoid antagonists (MRA); Angiotensin receptor-neprilysin inhibitor (ARNi)
- Active coronary disease
- Other causes of chronic heart failure (coronary artery disease, primary valvular heart disease, congenital heart disease)
- Other etiology of myocarditis requiring corticosteroids treatment as giant cells myocarditis, eosinophilic myocarditis and cardiac sarcoidosis or immune checkpoint inhibitor myocarditis
- Woman of childbearing potential without effective method of birth control (included contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, established proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices)
- Any medical and/or cognitive condition which limits the ability of participant to participate in study
- Pregnancy or breastfeeding
- Patient deprived of liberty or under Curatorship/Tutorship, safeguard of justice, according to French law
- Foreseeable inability, according to the investigator, to participate in all the visits, treatments and measures provided for in the protocol
- Patient not speaking or understanding French
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Refer to the "Detailed Description" section.
A vizsgálat 2 csoportja
- Experimental groupA vizsgált kezelés
Randomization in experimental group in addition to conventional HF therapy for 6 months.
Kezelés: Intravenous administration of Methylprednisolone és Oral Prednisone
- Control groupPlacebo, összehasonlításként
Randomization in control group in addition to conventional HF therapy for 6 months.
Kezelés: Perfusion of placebo és Oral Prednisone placebo
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- Use of Glucocorticoids Therapy in Acute Myocarditis With Severe Left Ventricular Dysfunction: a Multicenter Randomized Controlled Trial
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2024. július 29.